Higher prevalence of chronic pain, high-impact chronic pain for women, older adults, rural residents.
Comprehensive bipartisan package earmarks billions of dollars to fight opioid abuse in the United States.
Cassipa combines buprenorphine, an opioid (partial agonist-antagonist), and naloxone, an opioid antagonist.
In a randomized control trial, researchers found that internet-delivered exposure therapy was more cost-effective for patients with fibromyalgia than a waitlist control, which did not involve any treatment during the experimental phase of the study.
An elderly man presents to the emergency department with elbow and biceps pain after falling on the stairs.
Although literature indicates bidirectional associations between sleep disturbances and pain, few longitudinal studies have examined the role of sleep disturbances in contributing to chronic pain.
Increase in mean OMEs filled in initial opioid rx after hydrocodone's change from schedule III to II.
The number of patients prescribed opioids and visiting an emergency department or requiring hospitalization decreased from 2009 to 2015.
Dose-response association with highest odds of opioid-related death with high-dose pregabalin.
Children with abdominal pain commonly had clinically significant anxiety, moderate disability, pain.
A low-literacy, pain self-management program delivered one-on-one by a health educator or in groups with lectures from experts over a period of 6 months may improve chronic pain outcomes.
Differences exist in race and gender in patients with chronic lower back pain, especially in pain sensitivity and severity due to aftersensations from mechanical punctuate pain and deep muscle hyperalgesia.
Findings based on analysis of motorcycle accident victims by helmet use.
Variation exists in opioid prescribing practices among clinicians in single-hospital systems, which prompts concern about the potential for opioid overprescribing.
There is a lack of evidence supporting the benefits of combination drug therapy over monotherapy for the management of low back pain and sciatica.
Cumulative incidence of opioid-related adverse events was 38.3 per 100,000 prescriptions.
This novel agent has low permeability across the blood-brain barrier, which slows its rate of entry into the brain and reduces dopamine release.
Odds of pre-op opioid use up with age 31 to 40 years, tobacco use, illicit drug use, depression.
Only 44 of parents would definitely go to ER if their child had headache that didn't improve with medication.
Radiofrequency denervation, typically used to treat lumbar and cervical zygapophyseal joint pain, has shown efficacy in treating thoracic zygapophyseal joint pain.
American emergency medicine physicians have been taking measures to address the ongoing opioid crisis, which affects emergency departments throughout the country.
Investigators examined rates, predictors, and outcomes of neuroimaging in pediatric and adolescent patients who presented to the ED with a headache.
Surgeon General Jerome M. Adams, M.D., M.P.H., has urged more Americans to carry naloxone, an FDA-approved medication that can be delivered via nasal mist or injection and can temporarily suspend the effects of opioid overdose.
A panel discussion event held at the US Food and Drug Administration gathered patients with chronic pain and FDA officials, to reconcile concerns around prescriptions of opioid medications with the needs of these patient populations.
Commission makes 6 recommendations to meet 2030 goals for non-communicable diseases
Chronic low back pain (LBP) defined as persistent or fluctuating musculoskeletal pain of lower back and lumbar spine lasting >3 months.
In adults with sickle cell disease, higher daily opioid use may be associated with poorer health-related quality of life.
A study assessing the impact of upscheduling of hydrocodone combined medications on APRN practices in Oklahoma revealed significant barriers to effective pain management.
Researchers deployed a survey to individuals who had received treatment for opioid use disorder to assess their use of buprenorphine.
The phase 3 SUMMIT-07 trial assessed the safety, efficacy, and tolerability of a new mu-opioid receptor agonist analgesic in adults with moderate to severe chronic lower back pain.